Loading asset research
Kalaris Therapeutics Inc. Common Stock
KLRSNasdaq · USD · StocksQuote as of · Exchange session not verified$3.38
+2.42%
Today
KLRS
Loading 1D prices…
Market cap
$80.5M
Volume
95.1K
52w high
$11.8852w low
$3.03Company profile
Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Berkeley Heights, NJ, United States
Employees
20
Fiscal year end
1231
CIK
1754068
Session & valuation
Open$3.39
Previous close$3.30
Day high$3.44
Day low$3.27
30-day avg. volume58.4K
Outstanding shares23.8M
Diluted EPS-$2.85
Latest annual period
P/E (trailing)-1.19
P/E (forward)-2.04
Price / book1.39
Beta—
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| PTHSPelthos Therapeutics Inc. Common Stock | $83.8M | $16.8M | -257.93% | -$23.04 | -2.36% | Buy |
| BSEMBioStem Technologies Inc. Common Stock | $76.9M | $301.8M | +10.56% | $1.47 | +3.23% | Buy |
| OKYOOKYO Pharma Limited Ordinary Shares | $73.5M | $0.00 | — | -$0.24 | -2.80% | Buy |
| CSBRChampions Oncology Inc. Common Stock | $71M | $59.4M | -0.00% | -$0.08 | 0.00% | Unrated |
| CGTXCognition Therapeutics Inc. Common Stock | $93.5M | $0.00 | — | -$0.32 | +0.31% | Buy |